Telix Pharmaceuticals Limited

Happy Thanksgiving to our U.S. colleagues, partners, friends, and their families! We’re thankful for your collaboration, support, and the many ways you help us make a difference for patients. Wishing you a day filled with good food, laughter, and time with the people you love.

Telix has officially opened Telix Manufacturing Solutions (TMS) in Yokohama, Japan, our first cyclotron facility in the Asia Pacific region. The opening was commemorated with a lecture delivered by Professor Jun Hatazawa, Vice President of the Japan Isotope Association, on “Trends and Challenges for the Future of Nuclear Medicine.” The site will initially support clinical supply of TLX250-CDx in the region for kidney cancer imaging, with plans to expand to additional investigational and future commercial products, subject to regulatory approval. Read more here: https://bit.ly/49EmHUX TLX250-CDx has not received a marketing authorization in any jurisdiction.

Results from the ZIRCON-X study show that almost half of all patients imaged with Telix’s kidney cancer imaging candidate, TLX250-CDx (Zircaix®), would have undergone a change in clinical management when compared with baseline standard-of-care imaging. New analysis found that 48.6% of patients would have experienced a management change, and over 20% of these patients could have potentially avoided invasive biopsy. More than a third of evaluable patients would have undergone a major change, including escalation or de-escalation of treatment. ZIRCON-X was a non-interventional, prospective, post-hoc study using imaging data from the parent pivotal Phase 3 ZIRCON study to assess the impact of TLX250-CDx PET/CT on decision-making for patients with indeterminate renal masses (IRMs). The data will be presented at the 26th Annual Meeting of the Society of Urologic Oncology (SUO) being held in Phoenix, AZ from December 2 to 5. Read more on our website: https://bit.ly/3XB7LzB TLX250-CDx has not received a marketing authorization in any jurisdiction. Brand name subject to final regulatory approval.

During #WorldQualityWeek, we’re celebrating the culture of Quality that underpins everything we do at Telix. Rujeela, one of our Quality Leads, discusses how Quality is a shared responsibility across every part of the organization - built on collaboration, problem-solving, and a constant focus on patients. It’s how we continuously improve and deliver safe, reliable, and innovative products that make a difference for patients worldwide. Do you see yourself at Telix? Explore open roles and learn more about our culture: https://lnkd.in/gZ8up8qr #WorldQualityWeek #QualityCulture #TelixPharma #CareersAtTelix

Final results from the Phase 2 OPALESCENCE trial of TLX250-CDx (⁸⁹Zr-girentuximab) in metastatic triple negative breast cancer (mTNBC) have been published in the European Journal of Nuclear Medicine and Molecular Imaging. The investigator-initiated trial - conducted at Institut de Cancérologie de l'Ouest (ICO) in France under the supervision of Dr. Caroline Rousseau - evaluated the safety and diagnostic utility of Telix’s CAIX-targeting PET imaging candidate in this aggressive breast cancer subtype, as proof of concept for therapy. Authors conclude that TLX250-CDx “is a sensitive imaging method and offers promise for novel theranostics for mTNBC patients”. These findings build on a growing body of evidence supporting the expansion of Telix’s CAIX-targeting theranostic programs into new indications beyond kidney cancer. Read more on our website: https://bit.ly/43s7VwJ TLX250-CDx has not received a marketing authorization in any jurisdiction.

Today, on Veterans Day, we honor the courage, sacrifice, and service of all Veterans. As we pause to recognize their dedication, we are reminded of the importance of supporting their ongoing health and wellbeing. Prostate cancer affects Veterans at higher rates, and awareness, early detection, and access to care can make a life-changing difference. We also acknowledge the incredible Veterans working at Telix. Their dedication to our mission and improving patient outcomes is a testament to the strength and commitment shown by Veterans everywhere. Thank you to all who have served, and to those who continue to serve🎗️ For prostate cancer resources for Veterans, see here: https://lnkd.in/g_mh9xUt ZERO Prostate Cancer Prostate Cancer Foundation U.S. Department of Veterans Affairs

Join Telix at two upcoming investor conferences to learn more about the company’s growth strategy, commercial progress, and theranostic pipeline. 🔵 Kevin Richardson, CEO, Precision Medicine, will join a fireside chat at the UBS Global Healthcare Conference. 🔵 Richard Valeix, CEO, Therapeutics, will take part in a fireside chat at the Jefferies Global Healthcare Conference. Both sessions will be webcast live and available on demand. For details and registration, visit: https://lnkd.in/gcMhErzh

A new home for Telix clinical trials. Finding the right trial can often be complex. Telix’s new Clinical Trials page is designed to make information about our global theranostic studies easier to find and navigate for patients, carers and the wider community. With clear summaries, straightforward navigation and regularly updated content, the site supports greater awareness and access to information about our clinical programs. 🔗 Explore the new site: https://lnkd.in/gnW4ReRm

These shoes represent the nearly 2,000 Australians diagnosed with a brain tumor each year. Each pair tells a story of a life changed and a call for greater action. Today, Telix proudly supports Brain Tumour Alliance Australia’s Head to the Hill event at Parliament House in Canberra, bringing together patients, families, carers and researchers to highlight the impact of brain tumors. Alongside Hon. Minister Mark Butler, Richard Scolyer AO and Gail O’Brien AO, BTAA Chair Craig Cardinal launched the first Australian Brain Tumour Landscape Report, calling for stronger Government support for brain cancer research, clinical care and patient services. At Telix, we’re committed to improving outcomes for people with brain cancer. Our theranostic candidates combine targeted radiopharmaceutical therapy with diagnostic imaging to potentially help physicians better see, track and treat disease. Learn more about our neuro-oncology portfolio: https://lnkd.in/gV42ptBE Read the report: https://lnkd.in/ebjyznkk

TLX250-CDx (Zircaix®, ⁸⁹Zr-DFO-girentuximab), Telix’s kidney cancer imaging candidate, has been included in latest international guidelines for the molecular imaging of renal masses. Published on the SNMMI website and in The Journal of Nuclear Medicine, the guidelines recognize the emerging role of molecular imaging in the characterization and management of indeterminate renal lesions. The expert panel notes that TLX250-CDx PET "appears to be a well-tolerated and accurate method for non-invasive identification of clear cell renal cell carcinoma (ccRCC)", supported by data from Telix's pivotal Phase 3 ZIRCON trial. Read more on our website here: https://bit.ly/3JsiDwh